ZEVTERA Drug Patent Profile
✉ Email this page to a colleague
When do Zevtera patents expire, and when can generic versions of Zevtera launch?
Zevtera is a drug marketed by Basilea Pharm Allsch and is included in one NDA.
The generic ingredient in ZEVTERA is ceftobiprole medocaril sodium. There is one drug master file entry for this compound. Additional details are available on the ceftobiprole medocaril sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZEVTERA?
- What are the global sales for ZEVTERA?
- What is Average Wholesale Price for ZEVTERA?
Summary for ZEVTERA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | ZEVTERA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZEVTERA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ZEVTERA
ZEVTERA is protected by zero US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZEVTERA is ⤷ Sign Up.
This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting ZEVTERA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basilea Pharm Allsch | ZEVTERA | ceftobiprole medocaril sodium | POWDER;INTRAVENOUS | 218275-001 | Apr 3, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Basilea Pharm Allsch | ZEVTERA | ceftobiprole medocaril sodium | POWDER;INTRAVENOUS | 218275-001 | Apr 3, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
